Compared to Estimates, HCA (HCA) Q1 Earnings: A Look at Key Metrics
HCA Healthcare (HCA) reported $18.32 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 5.7%. EPS of $6.45 for the same period compares to $5.36 a year ago.The reported revenue represents a surprise of +0.08% over the Zacks Consensus Estimate of $18.31 billion. With the consensus EPS estimate being $5.77, the EPS surprise was +11.79%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how HCA performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Equivalent Admissions: 1.01 billion versus the five-analyst average estimate of 1.02 billion. Revenue per Equivalent Admission: $18,102 versus $18,026.95 estimated by five analysts on average. Equivalent Patient Days: 4.98 million compared to the 4.96 million average estimate based on three analysts. Admissions: 576.36 million versus 579.28 million estimated by three analysts on average. Number of freestanding outpatient surgery centers: 125 versus the two-analyst average estimate of 124. Patient Days: 2,836.62 Days compared to the 2,817.09 Days average estimate based on two analysts. Average Length of Stay: 5 compared to the 5 average estimate based on two analysts. Inpatient Revenue per Admission: $19,349 versus the two-analyst average estimate of $19,580.02. Number of hospitals: 192 versus the two-analyst average estimate of 191. Licensed Beds at End of Period: 50,571 versus 50,132 estimated by two analysts on average. View all Key Company Metrics for HCA here>>>Shares of HCA have returned -0.3% over the past month versus the Zacks S&P 500 composite's -4.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report HCA Healthcare, Inc. (HCA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Quelle: Zacks
Nachrichten zu HCA Inc.
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Analysen zu HCA Inc.
Datum | Rating | Analyst | |
---|---|---|---|
09.11.2016 | HCA Neutral | Mizuho | |
28.10.2016 | HCA Outperform | RBC Capital Markets | |
04.05.2016 | HCA Outperform | Wedbush Morgan Securities Inc. | |
04.05.2016 | HCA Outperform | RBC Capital Markets | |
28.10.2015 | HCA Overweight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
28.10.2016 | HCA Outperform | RBC Capital Markets | |
04.05.2016 | HCA Outperform | Wedbush Morgan Securities Inc. | |
04.05.2016 | HCA Outperform | RBC Capital Markets | |
28.10.2015 | HCA Overweight | Barclays Capital | |
28.10.2015 | HCA Outperform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
09.11.2016 | HCA Neutral | Mizuho | |
28.12.2005 | Update HCA Inc.: Hold | Deutsche Securities | |
16.09.2005 | Update HCA Inc.: Equal-weight | Morgan Stanley | |
24.01.2005 | Update HCA Inc.: Neutral | UBS | |
04.01.2005 | Update HCA Inc.: Market Perform | U.S. Bancorp Piper Jaffray |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für HCA Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen